Listen as expert faculty discuss key studies influencing their practice following the IAS 2021 Conference, including results from studies on HIV and COVID-19 outcomes; virologic, metabolic, and safety outcomes of 2DR with DTG/3TC; long-acting CAB plus RPV for ART in treatment-naive and heavily treatment–experienced PWH; investigational antiretroviral agents, lenacapavir and islatravir; and alternative dosing of BPaL for MDR-TB.
Listen as expert faculty discuss key studies influencing their practice following the IAS 2021 Conference, including results from studies on HIV and COVID-19 outcomes; virologic, metabolic, and safety outcomes of 2DR with DTG/3TC; long-acting CAB plus RPV for ART in treatment-naive and heavily treatment–experienced PWH; investigational antiretroviral agents, lenacapavir and islatravir; and alternative dosing of BPaL for MDR-TB.
Download this expert-authored slideset to review the most clinically relevant new data presented at IAS 2021 covering a wide range of HIV management topics, including HIV and COVID-19 outcomes, 2-drug ART, long-acting injectable ART, investigational ART, and TB treatment options.
Watch expert faculty present and discuss with one another some of the most clinically relevant data presented at IAS 2021, including results from studies on COVID-19 outcomes among PWH, 2-drug ART regimens, long-acting injectable ART, novel ART in development, and drug therapy for multidrug-resistant TB.
Watch this dynamic video module in which CCO’s expert faculty, Drs. Eric Daar and Renslow Sherer, present and discuss with one another some of the most clinically relevant new data presented at CROI 2021, including results from studies on HIV PrEP strategies, COVID-19 outcomes among PWH, ART during pregnancy/postpartum period, long-term use of current ART, and novel ART strategies in late-phase development.
Download this expert-authored slideset to review the most clinically relevant new data presented at CROI 2021 covering a wide range of HIV management topics, including HIV PrEP strategies; ART in pregnancy, the postpartum period, and adolescence; current and investigational ART; and coinfections.
Listen to expert insights from Daniel R. Kuritzkes, MD, and Michelle S. Cespedes, MD, MS, on updates from virtual CROI 2021, including new data on first-line ART and results from the ATLAS 2M and CAPELLA trials.
Gain expert insights on treatment strategies for complex HIV cases; topics include managing ART in heavily treatment-experienced patients, modifying ART in patients with underlying ARV resistance, and considerations for first-line ART selection in patients with obesity.
Download this expert-authored slideset to review treatment strategies for complex HIV cases; topics include managing heavily treatment-experienced patients, modifying ART in patients with underlying ARV resistance, and considerations for first-line ART selection in patients with obesity.
Gain expert insights on important clinical questions related to first-line ART, switch strategies for patients with virologic suppression, and use of antiretroviral drugs to prevent HIV infection, with an emphasis on the role of new and emerging strategies.
Download this expert-authored slideset to consider important clinical questions related to first-line ART, long-acting antiretroviral drugs, and 2-drug regimens for ART, with an emphasis on the role of new and emerging strategies.
Listen as expert faculty consider important clinical questions related to rapid ART initiation, long-acting antiretroviral drugs, and 2-drug regimens for ART, with an emphasis on the role of new and emerging strategies in the treatment of HIV.
Download this expert-authored slideset reviewing the latest data on HIV prevention, including PrEP uptake, current PrEP options, and next-generation PrEP options.
Listen to expert insights from W. David Hardy, MD, on current options for pre-exposure prophylaxis and exciting new data on next-generation HIV prevention.
Are you abreast of what is in the pipeline for HIV prevention? Listen to expert discussion by Joseph J. Eron, Jr., MD, on 4 investigational agents for HIV prevention.
Gain expert insights on treatment strategies for heavily treatment–experienced patients with HIV. Topics include assessment of virologic failure, current treatment options for patients with multiclass drug resistance, and guidance on selecting the next line of therapy for patients experiencing virologic failure due to resistance.
Download this expert-authored slideset to review guidelines and key data on assessing virologic failure, current management options for patients with multiclass drug resistance experiencing treatment failure, and considerations for switching ART in patients with underlying resistance.
Listen as expert faculty consider important clinical questions related to heavily treatment–experienced patients with HIV, including managing virologic failure and switching ART in the presence of underlying drug resistance.
Listen as expert faculty consider important clinical questions related to heavily treatment–experienced patients with HIV, including managing virologic failure and switching ART in the presence of underlying drug resistance.
Listen as expert faculty consider important clinical questions related to heavily treatment–experienced patients with HIV, including managing virologic failure and switching ART in the presence of underlying drug resistance.
Listen to expert insights from William R. Short, MD, MPH, AAHIVS, on optimizing initial antiretroviral therapy for treatment-naive patients with HIV.
Listen to expert insights from David A. Wohl, MD, on initiating antiretroviral therapy for a treatment-naive patient with HIV, HBV, and obesity.
Download this expert-authored slideset to review national guidelines, key study data, and individual considerations for optimizing the use of current ART regimens as initial HIV treatment and in switch strategies for patients with viral suppression who require a change in therapy.
Download this expert-authored slideset to review national guidelines, key study data, and individual considerations for individualizing first-line ART regimens to treat HIV.
Download this expert-authored slideset to review guidelines and key data on assessing virologic failure, current management options for patients with multiclass drug resistance experiencing treatment failure, and considerations for switching ART in patients with underlying resistance.
Review guidelines and key data on modifying ART in virologically suppressed patients, including switching ART to decrease pill burden and avoid comorbidities, switching to a long-acting injectable, and simplifying ART in the context of known multidrug resistance.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.